(NASDAQ: IRWD) Ironwood Pharmaceuticals's forecast annual revenue growth rate of -10.07% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.9%.
Ironwood Pharmaceuticals's revenue in 2025 is $317,676,000.On average, 3 Wall Street analysts forecast IRWD's revenue for 2025 to be $43,247,972,576, with the lowest IRWD revenue forecast at $42,717,203,475, and the highest IRWD revenue forecast at $44,306,274,382. On average, 3 Wall Street analysts forecast IRWD's revenue for 2026 to be $41,082,175,731, with the lowest IRWD revenue forecast at $39,613,498,790, and the highest IRWD revenue forecast at $42,720,439,872.
In 2027, IRWD is forecast to generate $36,935,380,306 in revenue, with the lowest revenue forecast at $36,571,285,648 and the highest revenue forecast at $37,299,474,964.